Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT201302261030N12
IRCT201302261030N12
Completed
Phase 2

Efficacy of Imatinib Mesylate in the treatment of refractory cutaneous chronic Graft Versus-Host Disease

Hematology-Oncology and SCT Research Center0 sites28 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionscutaneous cGVHD.Graft-versus-host reaction or disease

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
cutaneous cGVHD.
Sponsor
Hematology-Oncology and SCT Research Center
Enrollment
28
Status
Completed
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hematology-Oncology and SCT Research Center

Eligibility Criteria

Inclusion Criteria

  • •Inclusion Criteria
  • •1\- The patient shall undergo allogen bone marrow transplantation and have clinical and pathological cutaneous CGVHD criteria.
  • •2\- Patient’s cutaneous signs are not improved by taking corticosteroids with doses of 0\.5 mg/kg at least for 3 months and cyclosporine.
  • •3\- The cutaneous signs shall be active.
  • •4\- The patient shall be aged between 16 to 60 years old.
  • •Exclusion Criteria
  • •1\- Pregnancy
  • •2\- Having a history of taking Rituximab.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Phase II study of imatinib mesylate for treatment of Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in children: A Japanese Cooperative TrialPhiladelphia Chromosome-positive acute lymphoblastic leukemia
JPRN-C000000290Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)56
Active, not recruiting
Not Applicable
THERAPEUTIC AND BIOLOGICAL EFFECTS OF IMATINIB MESYLATE (STI571) IN PRIMARY HYPERESINOPHILIC SYNDROME (HES), CHRONIC EOSINOPHILIC LEUKEMIA (CEL) AND CHRONIC IDIOPHATIC HYPEREOSINOPHILIA (CIH): A STUDY FROM THE NORTHEN ITALY LEUKEMIA GROUP (NILG)
EUCTR2004-002280-24-ITAZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO (A.O. DI RILIEVO NAZIONALE)
Recruiting
Phase 1
Safety and efficacy of imatinib therapy administered in patients with Pulmonary Tumor Thrombotic Microangiopathy (PTTM) : A prospective studyPatients with malignancy, suspected of Pulmonary Tumor Thrombotic Microangiopathy (PTTM)
JPRN-jRCTs031210263Hatano Masaru20
Completed
Phase 3
se of memantin in treatment of adult with attention deficit hyperactivity disorderAdult ADHD (Attention-deficit hyperactivity disorder ).Disturbance of activity and attention
IRCT2016053028182N1Kurdistan University of Medical science40
Active, not recruiting
Phase 1
Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index. Multicenter, prospective, randomized study.Patients with intermediate-risk gastrointestinal stromal tumor presenting a high Genomic Grade IndexTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2014-005255-87-FRAssistance Publique Hôpitaux de MARSEILLE80